Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04272034. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors
Study identification
- NCT ID
- NCT04272034
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 105 participants
Conditions and interventions
Conditions
- Advanced Solid Tumors
- Anal Carcinoma
- Basal Cell Carcinoma (Unresectable or Metastatic)
- Cervical Cancer
- Clear Cell Ovarian or Endometrial Carcinoma
- Cutaneous Squamous Cell Carcinoma
- Cyclin-dependent Kinase 12 Mutated Tumors
- DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
- Esophageal Squamous Cell Carcinoma
- MSI-H/dMMR Tumors
- Merkel Cell Carcinoma
- Mesothelioma
- Nasopharyngeal Carcinoma
- PD-L1 Amplified Tumor (9p24.1)
- Sarcomatoid Renal Cell Carcinoma
- Small-cell Lung Cancer
- Squamous Cell Penile Carcinoma
- Urothelial Carcinoma, HCC
Interventions
- INCB099318 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2021
- Primary completion
- Aug 15, 2024
- Completion
- Aug 15, 2024
- Last update posted
- Oct 15, 2025
2021 – 2024
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Prisma Health Cancer Institute Faris | Greenville | South Carolina | 29605 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04272034, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04272034 live on ClinicalTrials.gov.